• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email
    SC 13G/A 1 tm2427620d25_sc13ga.htm SC 13G/A

     

     

         
      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

    Q32 Bio Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    746964105

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    5AM Ventures IV, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware, United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    PN

     

    (1)This Schedule 13G is filed by 5AM Ventures IV, L.P., a Delaware limited partnership (“Ventures IV”), 5AM Co-Investors IV, L.P., a Delaware limited partnership (“Co-Investors IV”), 5AM Partners IV, LLC, a Delaware limited liability company (“Partners IV”), Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”), and Dr. Scott M. Rocklage (“Rocklage” and together with Ventures IV, Co-Investors IV, Partners IV, Diekman and Schwab, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    2

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    5AM Co-Investors IV, L.P.
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware, United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    PN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    3

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    5AM Partners IV, LLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware, United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    4

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    Dr. John D. Diekman
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    5

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    Andrew J. Schwab
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    6

     

     

    CUSIP No. 746964105
     
      1. Names of Reporting Persons
    Dr. Scott M. Rocklage
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States of America

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0 shares
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    0 shares
     
    8. Shared Dispositive Power
    0 shares

     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    0 shares
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    0.0%
     
      12. Type of Reporting Person (See Instructions)
    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    7

     

     

    Item 1.
      (a)

    Name of Issuer
    Q32 Bio Inc.

    (f/k/a Homology Medicines, Inc.)

      (b)

    Address of Issuer’s Principal Executive Offices
    830 Winter Street

    Waltham, MA 02451

     
    Item 2.
      (a)

    Name of Person Filing
    5AM Ventures IV, L.P. (“Ventures IV”)

    5AM Co-Investors IV, L.P. (“Co-Investors IV”)

    5AM Partners IV, LLC (“Partners IV”)

    Dr. John D. Diekman (“Diekman”)

    Andrew J. Schwab (“Schwab”)

    Dr. Scott M. Rocklage (“Rocklage”)

      (b)

    Address of Principal Business Office or, if none, Residence
    c/o 5AM Ventures

    4 Embarcadero Center, Suite 3110
    San Francisco, CA 94111

      (c) Citizenship      
        Entities: 5AM Ventures IV, L.P. - Delaware
          5AM Co-Investors IV, L.P. - Delaware
          5AM Partners IV, LLC - Delaware
               
        Individuals: Diekman - United States of America
          Schwab - United States of America
          Rocklage - United States of America
      (d) Title of Class of Securities
    Common Stock
      (e) CUSIP Number
    746964105

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable.

     

    8

     

     

    Item 4. Ownership

     

    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of September 30, 2024:
     
      (a)

    Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person

      (b)

    Percent of class:

    See Row 11 of cover page for each Reporting Person

      (c) Number of shares as to which the person has:
        (i)

    Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

        (ii)

    Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

        (iii)

    Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

        (iv)

    Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable.
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
     
    Item 10. Certification

     

      Not applicable.

     

    9

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    5AM Ventures IV, L.P.   5AM Co-Investors IV, L.P.
         
    By: 5AM Partners IV, LLC   By: 5AM Partners IV, LLC
    its General Partner   its General Partner
         
    By: /s/ Andrew J. Schwab   By: /s/ Andrew J. Schwab
      Name: Andrew J. Schwab     Name: Andrew J. Schwab
      Title: Managing Member     Title: Managing Member
         
    5AM Partners IV, LLC    
         
    By: /s/ Andrew J. Schwab    
      Name: Andrew J. Schwab    
      Title: Managing Member    
         
      /s/ Dr. John D. Diekman     /s/ Andrew J. Schwab
      Dr. John D. Diekman     Andrew J. Schwab
         
      /s/ Dr. Scott M. Rocklage      
      Dr. Scott M. Rocklage      

     

      ATTENTION  
         
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    10

     

     

    Exhibit(s):

     

    A - Joint Filing Statement

     

    11

     

     

    EXHIBIT A

     

    JOINT FILING STATEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Q32 Bio, Inc. is filed on behalf of each of us.

     

    Dated: November 14, 2024

     

    5AM Ventures IV, L.P.   5AM Co-Investors IV, L.P.
         
    By: 5AM Partners IV, LLC   By: 5AM Partners IV, LLC
    its General Partner   its General Partner
         
    By: /s/ Andrew J. Schwab   By: /s/ Andrew J. Schwab
      Name: Andrew J. Schwab     Name: Andrew J. Schwab
      Title: Managing Member     Title: Managing Member
         
    5AM Partners IV, LLC    
         
    By: /s/ Andrew J. Schwab    
      Name: Andrew J. Schwab    
      Title: Managing Member    
         
      /s/ Dr. John D. Diekman     /s/ Andrew J. Schwab
      Dr. John D. Diekman     Andrew J. Schwab
         
      /s/ Dr. Scott M. Rocklage      
      Dr. Scott M. Rocklage      

     

    12

     

    Get the next $QTTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    2/25/2026$13.00Buy
    H.C. Wainwright
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    12/6/2024$64.00Outperform
    BMO Capital Markets
    More analyst ratings

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Morrison Jodie Pope sold $44,675 worth of shares (9,896 units at $4.51), decreasing direct ownership by 10% to 89,104 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    2/27/26 7:00:04 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Violette Shelia M. sold $12,708 worth of shares (2,815 units at $4.51), decreasing direct ownership by 5% to 55,569 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    2/27/26 7:00:03 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and President Kalowski Lee sold $18,035 worth of shares (3,995 units at $4.51), decreasing direct ownership by 10% to 35,943 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    2/27/26 7:00:09 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

    2/18/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Announces $10.5 Million Registered Direct Offering

    WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor.Q32 Bio has entered into a definitive agreement for the issuance and sale of 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares of common stock at an offering price of $3.90 per share of common stock, which was the closing pric

    2/17/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Q32 Bio with a new price target

    H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

    2/25/26 7:53:48 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

    2/11/25 7:55:03 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Q32 Bio from Overweight to Neutral and set a new price target of $4.00 from $20.00 previously

    2/11/25 7:11:28 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Q32 Bio Inc.

    SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)

    2/20/26 8:13:47 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Q32 Bio Inc.

    SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)

    2/19/26 4:59:09 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Q32 Bio Inc.

    8-K - Q32 Bio Inc. (0001661998) (Filer)

    2/17/26 4:18:22 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Financials

    Live finance-specific insights

    View All

    Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targe

    2/18/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Announces Establishment of Rare Kidney Disease Pipeline

    Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both trials planned to start treating subjects in 2026 CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: A

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Q32 Bio Inc.

    SC 13G - Q32 Bio Inc. (0001661998) (Subject)

    11/13/24 4:05:13 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    10/25/24 6:06:25 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care